Truyền tín hiệu và sự điều tiết apoptosis: vai trò của ceramide

Lockshin RA. The early modern period in cell death. Cell Death Differ 1997; 4: 347-351.

Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.

Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.

Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986; 44: 817-829.

Hengartner MO, Horvitz HR. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian protooncogene bcl-2. Cell 1994; 76: 665-676.

Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell 1993; 75: 641-652.

Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.

Winoto A. Cell death in the regulation of immune responses. Curr Opin Immunol 1997; 9: 365-370.

Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997; 89: 1845-1853.

Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.

Ellis RE, Yuan JY, Horvitz HR. Mechanisms and functions of cell death. Annu Rev Cell Biol 1991; 7: 663-698.

Hengartner MO, Ellis RE, Horvitz HR. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 1992; 356: 494-499.

Shaham S, Horvitz HR. An alternatively spliced C. elegans ced-4 RNA encodes a novel cell death inhibitor. Cell 1996; 86: 201-208.

Xue D, Horvitz HR. Caenorhabditis elegans CED-9 protein is a bifunctional cell-death inhibitor. Nature 1997; 390: 305-308.

Spector MS, Desnoyers S, Hoeppner DJ, Hengartner MO. Interaction between the C. elegans cell-death regulators CED-9 and CED-4. Nature 1997; 385: 653-656.

Chinnaiyan AM, O'Rourke K, Lane BR, Dixit VM. Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science 1997; 275: 1122-1126.

Wu D, Wallen HD, Nuñez G. Interaction and regulation of subcellular localization of CED-4 by CED-9. Science 1997; 275: 1126-1129.

Xue D, Horvitz HR. Inhibition of the Caenorhabditis elegans cell-death protease CED-3 by a CED-3 cleavage site in baculovirus p35 protein. Nature 1995; 377: 248-251.

Hagunin M, Quintal LJ, Mankovich JA, Ghayur T. Protease activity of in vitro transcribed and translated Caenorhabditis elegans cell death gene (ced-3) product. J Biol Chem 1996; 271: 3517-3522.

Xue D, Shaham S, Horvitz HR. The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Genes Dev 1996; 10: 1073-1083.

Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405-413.

Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489.

Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132.

Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-1136.

Shaham S, Horvitz HR. Developing Caenorhabditis elegans neurons may contain both cell-death protective and killer activities. Genes Dev 1996; 10: 578-591.

Hengartner MO, Horvitz HR. Activation of C. elegans cell death protein CED-9 by an amino-acid substitution in a domain conserved in Bcl-2. Nature 1994; 369: 318-320.

Alnemri ES, Livingston DJ, Nicholson DW, et al. Human ICE/CED-3 protease nomenclature. Cell 1996; 87: 171.

Margolin N, Raybuck SA, Wilson KP, et al. Substrate and inhibitor specificity of interleukin-1 β-converting enzyme and related caspases. J Biol Chem 1997; 272: 7223-7228.

Talanian RV, Quinlan C, Trautz S, et al. Substrate specificities of caspase family proteases. J Biol Chem 1997; 272: 9677-9682.

Stennicke HR, Salvesen GS. Biochemical characteristics of caspases-3,-6,-7, and-8. J Biol Chem 1997; 272: 25719-25723.

Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? Cell 1995; 82: 349-352.

Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci, USA 1996; 93: 2239-2244.

Fraser A, Evan G. A license to Kill. Cell 1996; 85: 781-784.

Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997; 326: 1-16.

Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997; 91: 443-446.

Porter AG, Ng P, Janicke RU. Death substrates come alive. Bioessays 1997; 19: 501-507.

Peter ME, Kischkel FC, Scheuerpflug CG, Medema JP, Debatin KM, Krammer PH. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur J Immunol 1997; 27: 1207-1212.

Dbaibo GS, Perry DK, Gamard CJ, et al. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)α: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J Exp Med 1997; 185: 481-490.

Obeid LM, Linardic CM, Karolak LA, Hannun YA. Programmed cell death induced by ceramide. Science 1993; 259: 1769-1771.

Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science 1996; 274: 1855-1859.

Wissing D, Mouritzen H, Egeblad M, Poirier GG, Jäättelä M. Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis. Proc Natl Acad Sci USA 1997; 94: 5073-5077.

Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today 1994; 15: 7-10.

Petit PX, Susin SA, Zamzami N, Mignotte B, Kroemer G. Mitochondria and programmed cell death: back to the future. FEBS Lett 1996; 396: 7-13.

Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387: 773-776.

Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994; 79: 189-192.

Yin X, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994; 369: 321-323.

White E. Life, death, and the pursuit of apoptosis. Genes Dev 1996; 10: 1-15.

Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 1982; 307: 1231-1236.

Vaux DS, Cory S, Adams J. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.

Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6.

Korsmeyer SJ. Regulators of cell death. Trends Genet 1995; 11: 101-105.

Deng G, Podack ER. Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc Natl Acad Sci USA 1993; 90: 2189-2193.

Armant M, Delespesse G, Sarfati M. IL-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression. Immunology 1995; 85: 331-337.

Choi MS, Boise LH, Gottschalk AR, Quintáns J, Thompson CB, Klaus GG. The role of bcl-XL in CD40-mediated rescue from anti-μ-induced apoptosis in WEHI-231 B lymphoma cells. Eur J Immunol 1995; 25: 1352-1357.

Fang W, Nath KA, Mackey MF, Noelle RJ, Mueller DL, Behrens TW. CD40 inhibits B cell apoptosis by upregulating bcl-xL expression and blocking oxidant accumulation. Am J Physiol 1997; 272: C950-956.

Broome HE, Dargan CM, Krajewski S, Reed JC. Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal. J Immunol 1995; 155: 2311-2317.

Lotem J, Sachs L. Regulation of bcl-2, bcl-XL and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth Differ 1995; 6: 647-653.

Chen M, Quintáns J, Fuks Z, Thompson C, Kufe DW, Weichselbaum RR. Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha, and ceramide. Cancer Res 1995; 55: 991-994.

Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995; 92: 4507-4511.

May SW, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2α in association with suppression of apoptosis. J Biol Chem 1994; 269: 26865-26870.

Haldar S, Jena N, Croce CM. Antiapoptosis potential of bcl-2 oncogene by dephosphorylation. Biochem Cell Biol 1994; 72: 455-462.

Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 1996; 87: 619-628.

Gajewski TF, Thompson CB. Apoptosis meets signal transduction: elimination of a BAD influence. Cell 1996; 87: 589-592.

Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-638.

Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.

del Peso L, González-García M, Page C, Herrera R, Nuñez G. Interleukin-3-induced phophorylation of BAD through the protein kinase Akt. Science 1997; 278: 687-689.

Franke TF, Cantley LC. A Bad kinase makes good. Nature 1997; 390: 116-117.

Hockenbery DM, Oltvai ZN, Yin X, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-251.

Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H, Tsujimoto Y. Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature 1995; 374: 811-813.

Jacobson MD, Raff MC. Programmed cell death and Bcl-2 protection in very low oxygen. Nature 1995; 374: 814-816.

Steinman HM. The Bcl-2 oncoprotein functions as a prooxidant. J Biol Chem 1995; 270: 3487-3490.

Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995; 92: 7834-7838.

Sato T, Hanada M, Bodrug S, et al. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 1994; 91: 9238-9242.

Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.

Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-291.

Cheng EH, Levine B, Boise LH, Thompson CB, Hardwick JM. Bax-independent inhibition of apoptosis by Bcl-XL. Nature 1996; 379: 554-556.

Clair EGS, Anderson SJ, Oltvai ZN. Bcl-2 counters apoptosis by bax heterodimerization-dependent and-independent mechanisms in the T-cell lineage. J Biol Chem 1997; 272: 29347-29355.

Zha H, Reed JC. Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J Biol Chem 1997; 272: 31482-31488.

Hacker G, Vaux DL. Apoptosis: a sticky business. Curr Biol 1995; 5: 622-624.

Golstein P. Controlling cell death. Science 1997; 275: 1081-1082.

Minn AJ, Vélez P, Schendel SL, et al. Bcl-xL forms an ion channel in synthetic lipid membranes. Nature 1997; 385: 353-357.

Schendel SL, Xie Z, Montal MO, Matsuyama S, Montal M, Reed JC. Channel formation by antiapoptotic protein Bcl-2. Proc Natl Acad Sci USA. 1997; 94: 5113-5118.

Kharbanda S, Pandey P, Schofield L, et al. Role for Bcl-xLas an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA. 1997; 94: 6939-6942.

Kim CN, Wang X, Huang Y, et al. Overexpression of Bcl-XLinhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res 1997; 57: 3115-3120.

He H, Lam M, McCormick TS, Distelhorst CW. Maintenance of calcium homeostasis in the endoplasmic reticulum by Bcl-2. J Cell Biol 1997; 138: 1219-1228.

Susin SA, Zamzami N, Castedo M, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 1996; 184: 1331-1341.

Antonsson B, Conti F, Ciavatta A, et al. Inhibition of Bax channel-forming activity by Bcl-2. Science 1997; 277: 370-372.

Borner C, Olivier R, Martinou I, Mattmann C, Tschopp J, Martinou JC. Dissection of functional domains in Bcl-2α by site-directed mutagenesis. Biochem Cell Biol 1994; 72:463-469.

Cheng EHY, Kirsch DG, Clem RJ, et al. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997; 278: 1966-1968.

Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76: 959-962.

Dhein J, Walczak H, Bäumler C, Debatin K, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995; 373: 438-441.

Brunner T, Mogil RJ, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373: 441-444.

Ju S, Panka DJ, Cui H, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444-448.

Chinnaiyan AM, O'Rourke K, Yu G, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996; 274: 990-992.

Marsters SA, Sheridan JP, Donahue CJ, et al. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr Biol 1996; 6: 1669-1676.

Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113.

Kitson J, Raven T, Jiang YP, et al. A death-domain-containing receptor that mediates apoptosis. Nature 1996; 384: 372-375.

Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815-818.

Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.

MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272: 25417-25420.

Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74: 845-853.

Itoh N, Nagata S. A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J Biol Chem 1993; 268: 10932-10937.

Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.

Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270: 7795-7798.

Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell 1995; 81: 495-504.

Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995; 81: 513-523.

Schievella AR, Chen JH, Graham JR, Lin LL. MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase. J Biol Chem 1997; 272: 12069-12075.

Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO1-and TNF receptor-induced cell death. Cell 1996; 85: 803-815.

Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/Apo-1) death-inducing signaling complex. Cell 1996; 85: 817-827.

Chinnaiyan AM, Tepper CG, Seldin MF, et al. FADD/MORT1 is a common mediator of CD 95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996; 271: 4961-4965.

Hsu H, Huang J, Shu H, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996; 4: 387-396.

Duan H, Dixit VM. RAIDD is a new ‘death’ adaptor molecule. Nature 1997; 385: 86-89.

Ahmad M, Srinivasula SM, Wang L, et al. CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP. Cancer Res 1997; 57: 615-619.

Vincenz C, Dixit VM. Fas-associated death domain protein interleukin-1β-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95-and p55-mediated death signaling. J Biol Chem 1997; 272: 6578-6583.

Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994; 78: 681-692.

Hsu H, Huang J, Shu H, Pan M, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84: 299-308.

Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 1996; 87: 565-576.

Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 1996; 782-784.

Wang CY, Mayo MW, Baldwin AS Jr. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996; 274: 784-787.

Shu HB, Halpin DR, Goeddel DV. Casper is a FADD-and caspase-related inducer of apoptosis. Immunity 1997; 6: 751-763.

Inohara N, Koseki T, Hu Y, Chen S, Núñez G. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc Natl Acad Sci USA. 1997; 94: 10717-10722.

Han DKM, Chaudhary PM, Wright ME, et al. MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death. Proc Natl Acad Sci USA. 1997; 94: 11333-11338.

Tewari M, Dixit VM. Fas-and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J Biol Chem 1995; 270: 3255-3260.

Beidler DR, Tewari M, Friesen PD, Poirier G, Dixit VM. The baculovirus p35 protein inhibits Fas-and tumor necrosis factor-induced apoptosis. J Biol Chem 1995; 270: 16526-16528.

Bump NJ, Hackett M, Hangunin M, et al. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science 1995; 269: 1885-1888.

Bertin J, Armstrong RC, Ottilie S, et al. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas-and TNFR1-induced apoptosis. Proc Natl Acad Sci USA. 1997; 94: 1172-1176.

Thome M, Schneider P, Hofmann K, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997; 386: 517-521.

Hu S, Vincenz C, Buller M, Dixit VM. A novel family of viral death effector domain-containing molecules that inhibit both CD-95-and tumor necrosis factor receptor-1-induced apoptosis. J Biol Chem 1997; 272: 9621-9624.

Clem RJ, Hardwick JM, Miller LK. Anti-apoptotic genes of baculoviruses. Cell Death Differ 1996; 3: 9-16.

Hawkins CJ, Uren AG, Hacker G, Medcalf R, Vaux DL. Inhibition of interleukin 1β-converting enzyme-mediated apoptosis of mammalian cells by baculovirus IAP. Proc Natl Acad Sci USA 1996; 93: 13786-13790.

Seshagiri S, Miller LK. Baculovirus inhibitors of apoptosis (IAPs) block activation of Sf-caspase-1. Proc Natl Acad Sci USA. 1997; 94: 13606-13611.

Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1-and CD-95-induced apoptosis. J Biol Chem 1997; 272: 17255-17257.

Srinivasula SM, Ahmad M, Ottilie S, et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 1997; 272: 18542-18545.

Rothe M, Pan M, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995; 83: 1243-1252.

Uren AG, Pakusch M, Hawkins CJ, Puls KL, Vaux DL. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc Natl Acad Sci USA. 1996; 93: 4974-4978.

Shu HB, Takeuchi M, Goeddel DV. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci USA. 1996; 93: 13973-13978.

Devereaux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300-304.

Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997; 16: 6914-6925.

Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526.

Canman CE, Chen CY, Lee MH, Kastan MB. DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harb Symp Quant Biol 1994; 59: 277-286.

Picksley SM, Lane DP. p53 and Rb: their cellular roles. Curr Opin Cell Biol 1994; 6: 853-858.

Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.

Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 1992; 89: 7491-7495.

Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-1828.

Steegenga WT, van der Eb AJ, Jochemsen AG. How phosphorylation regulates the activity of p53. J Mol Biol 1996; 263: 103-113.

Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90: 595-606.

Zhan Q, Bae I, Kastan MB, Fornace AJ Jr. The p53-dependent gamma-ray response of GADD45. Cancer Res 1994; 54: 2755-2760.

Smith ML, Chen I-T, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994; 266: 1376-1380.

Mummenbrauer T, Janus F, Müller B, Wiesmüller L, Deppert W, Grosse F. p53 protein exhibits 3′-to-5′ exonuclease activity. Cell 1996; 85: 1089-1099.

Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.

Debbas M, White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 1993; 7: 546-554.

Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-16.

El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.

El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.

Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.

Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.

Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995; 377: 552-557.

Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684.

Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.

Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.

Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54: 3131-3135.

Canman CE, Gilmer TM, Coutts SB, Kastan MB. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 1995; 9: 600-611.

Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-305.

Friesen C, Herr I, Krammer PH, Depatin K. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2: 574-577.

Müller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells involves activation of p53 and is mediated by the CD95/(APO-1/Fas) receptor/ligand system. J Clin Invest 1997; 99: 1-11.

Krammer PH. The tumor strikes back: new data on expression of the CD95(APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology. Cell Death Differ 1997; 4: 362-364.

Fuchs EJ, McKenna KA, Bedi A. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32b. Cancer Res 1997; 57: 2550-2554.

Villunger A, Egle A, Kos M, et al. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 1997; 57: 3331-3334.

Wu GS, Burns TF, McDonald ER 3rd, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-143.

Jacobson MD. Reactive oxygen species and programmed cell death. Trends Biochem Sci 1996; 21: 83-86.

Johnson TM, Yu Z, Ferrans VJ, Lowenstein RA, Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci USA. 1996; 93: 11848-11852.

Caelles C, Helmberg A, Karin M. p53-depndent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370: 220-223.

Shen Y, Shenk T. Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. Proc Natl Acad Sci USA. 1994; 91: 8940-8944.

Sabatini P, Chiou S, Rao L, White E. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol Cell Biol 1995; 15: 1060-1070.

Hannun YA. The Sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem 1994; 269: 3125-3128.

Hannun YA. Sphingolipid-Mediated Signal Transduction. Austin, Texas: R.G. Landes Company 1997: 188pp.

Okazaki T, Bielawska A, Bell RM, Hannun YA. Role of ceramide as a lipid mediator of 1α,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J Biol Chem 1990; 265: 15823-15831.

Jayadev S, Liu B, Bielawska AE, et al. Role for ceramide in cell cycle arrest. J Biol Chem 1995; 270: 2047-2052.

Dbaibo GS, Pushkareva MY, Jayadev S, et al. Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest. Proc Natl Acad Sci USA. 1995; 92: 1347-1351.

Venable ME, Lee JY, Smyth MJ, Bielawska A, Obeid LM. Role of ceramide in cellular senescence. J Biol Chem 1995; 270: 30701-30708.

Okazaki T, Bell RM, Hannun YA. Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. J Biol Chem 1989; 264: 19076-19080.

Kim M, Linardic C, Obeid L, Hannun Y. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor α and γ-interferon: specific role in cell differentiation. J Biol Chem 1991; 266: 484-489.

Niculescu F, Rus H, Shin S, Lang T, Shin ML. Generation of diacylglycerol and ceramide during homologous complement activation. J Immunol 1993; 150: 214-224.

Ballou LR, Chao CP, Holness MA, Barker SC, Raghow R. Interleukin-1-mediated PGE2 production and sphingomyelin metabolism. Evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide. J Biol Chem 1992; 267: 20044-20050.

Mathias S, Younes A, Kan C, Orlow I, Joseph C, Kolesnick RN. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1β. Science 1993; 259: 519-522.

Boucher LM, Wiegmann K, Futterer A, et al. CD28 signals through acidic sphingomyelinase. J Exp Med 1995; 181: 2059-2068.

Cifone MG, De Maria R, Roncaioli P, et al. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med 1994; 180: 1547-1552.

Tepper CG, Jayadev S, Liu B, et al. Role of ceramide as an endogenous mediator of Fas-induced cytotoxicity. Proc Natl Acad Sci USA. 1995; 92: 8443-8447.

Kolesnick R, Golde DW. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 1994; 77: 325-328.

Haimovitz-Friedman A, Kan CC, Ehleiter D, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 1994; 180: 525-535.

Strum JC, Small GW, Pauig SB, Daniel LW. 1-β-D-arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. J Biol Chem 1994; 269: 15493-15497.

Zhang J, Alter N, Reed JC, Borner C, Obeid LM, Hannun YA. Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proc Natl Acad Sci, USA. 1996; 93: 5325-5328.

Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick RN. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 1996; 82: 405-414.

Jaffrézou J, Levade T, Bettaïeb A, et al. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 1996; 15: 2417-2424.

Smyth MJ, Perry DK, Zhang J, Poirier GG, Hannun YA, Obeid LM. prICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of bcl-2. Biochem J 1996; 316: 25-28.

Cai Z, Bettaieb A, Mahdani NE, et al. Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-α-mediated cytotoxicity. J Biol Chem 1997; 272: 6918-6926.

Chmura SJ, Nodzenski E, Beckett MA, Kufe DW, Quintans J, Weichselbaum RR. Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res 1997; 57: 1270-1275.

Michael JM, Lavin MF, Watters DJ. Resistance to radiation-induced apoptosis in Burkitt's lymphoma cells is associated with defective ceramide signaling. Cancer Res 1997; 57: 3600-3605.

Chmura SJ, Mauceri HJ, Advani S, et al. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res 1997; 57: 4340-4347.

Lavie Y, Cao Ht, Volner A, et al. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 1997; 272: 1682-1687.

Dbaibo GS, Obeid LM, Hannun YA. TNFα signal transduction through ceramide: dissociation of growth inhibitory effects of TNFα from activation of NF-κB. J Biol Chem 1993; 268: 17762-17766.

Gamard CJ, Dbaibo GS, Liu B, Obeid LM, Hannun YA. Selective involvement of ceramide in cytokine-induced apoptosis. Ceramide inhibits phorbol ester activation of nuclear factor κB. J Biol Chem 1997; 272: 16474-16481.

Bielawska A, Crane HM, Liotta D, Obeid LM, Hannun YA. Selectivity of ceramide-mediated biology: lack of activity of erythro-dihydroceramide. J Biol Chem 1993; 268: 26226-26232.

Spence MW. Sphingomyelinases. Adv Lipid Res 1993; 26: 3-23.

Chatterjee S. Neutral sphingomyelinase. Adv Lipid Res 1993; 26: 25-47.

Okazaki T, Bielawska A, Domae N, Bell RM, Hannun YA. Characteristics and partial purification of a novel cytosolic, magnesium-independent, neutral sphingomyelinase activated in the early signal transduction of 1α,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J Biol Chem 1994; 269: 4070-4077.

Liu B, Obeid LM, Hannun YA. Sphingomyelinases in cell regulation. Sem Cell Dev Biol 1997; 8: 311-322.

Santana P, Peña LA, Haimovitz-Friedman A, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996; 86: 189-199.

Linardic CM, Hannun YA. Identification of a distinct pool of sphingomyelin involved in the sphingomyelin cycle. J Biol Chem 1994; 269: 23530-23537.

Andrieu N, Salvayre R, Levade T. Comparative study of the metabolic pools of sphingomyelin and phosphatidylcholine sensitive to tumor necrosis factor. Eur J Biochem 1996; 236: 738-745.

Zhang P, Liu B, Jenkins GM, Hannun YA, Obeid LM. Expression of neutral sphingomyelinase identifies a distinct pool of sphingomyelin involved in apoptosis. J Biol Chem 1997; 272: 9609-9612.

Liu J, Mathias S, Yang Z, Kolesnick RN. Renaturation and tumor necrosis factor-alpha stimulation of a 97-kDa ceramide-activated protein kinase. J Biol Chem 1994; 269: 3047-3052.

Zhang Y, Yao B, Delikat S, et al. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 1997; 89: 63-72.

Lozano J, Berra E, Municio MM, et al. Protein kinase C ζ isoform is critical for kB-dependent promoter activation by sphingomyelinase. J Biol Chem 1994; 269: 19200-19202.

Dobrowsky RT, Hannun YA. Ceramide stimulates a cytosolic protein phosphatase. J Biol Chem 1992; 267: 5048-5051.

Dobrowsky RT, Kamibayashi C, Mumby MC, Hannun YA. Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 1993; 268: 15523-15530.

Wolff RA, Dobrowsky RT, Bielawska A, Obeid LM, Hannun YA. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J Biol Chem 1994; 269: 19605-19609.

Fishbein JD, Dobrowsky RT, Bielawska A, Garrett S, Hannun YA. Ceramide-mediated biology and CAPP are conserved in Saccharomyces cerevisiae. J Biol Chem 1993; 268: 9255-9261.

Rani CS, Abe A, Chang Y, et al. Cell cycle arrest induced by an inhibitor of glucosylceramide synthase: Correlation with cyclin-dependent kinases. J Biol Chem 1995; 270: 2859-2867.

Bielawska A, Linardic CM, Hannun YA. Ceramide-mediated biology: determination of structural and stereospecific requirements through the use of N-acyl-phenylaminoalcohol analogs. J Biol Chem 1992; 267: 18493-18497.

Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA, Grant S. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci USA 1994; 91: 73-77.

Quintáns J, Kilkus J, McShan CL, Gottschalk AR, Dawson G. Ceramide mediates the apoptotic response of WEHI 231 cells to anti-immunoglobulin, corticosteroids and irradiation. Biochem Biophys Res Commun 1994; 202: 710-714.

Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53: 3976-3985.

Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994; 371: 346-347.

Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 β-converting enzyme. J Biol Chem 1994; 269: 30761-30764.

Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995; 81:801-809.

Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376: 37-43.

Duan H, Chinnaiyan AM, Hudson PL, Wing JP, He W, Dixit VM. ICE-LAP3, a novel mammalian homolog of the Caenorhabditis elegans cell death protein CED-3 is activated during Fas-and tumor necrosis factor-induced apoptosis. J Biol Chem 1996; 271: 1621-1625.

Mizushima N, Koike R, Kohsaka H, et al. Ceramide induces apoptosis via CPP32 activation. FEBS Lett 1996; 395: 267-271.

Kojima H, Datta R. Involvement of a CrmA-insensitive ICE/Ced-3-like protease in ceramide-induced apoptosis. Oncol Res 1996; 8: 497-501.

Allouche M, Bettaieb A, Vindis C, Rousse A, Grignon C, Laurent G. Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells. Oncogene 1997; 14: 1837-1845.

Martin SJ, Takayama S, McGahon AJ, et al. Inhibition of ceramide-induced apoptosis by Bcl-2. Cell Death Differ 1995; 2: 253-257.

Jayadev S, Linardic CM, Hannun YA. Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor α. J Biol Chem 1994; 269: 5757-5763.

Jayadev S, Hayter HL, Andrieu N, et al. Phospholipase A2 is necessary for tumor necrosis factor α-induced ceramide generation in L929 cells. J Biol Chem 1997; 272: 17196-17203.

Zimmerman RJ, Chan A, Leadon SA. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res 1989; 49: 1644-1648.

Schulze-Osthoff K, Bakkers AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions: evidence for the involvement of mitochondrial radical generation. J Biol Chem 1992; 267: 5317-5323.

Hennet T, Richter C, Peterhans E. Tumour necrosis factor-α induces superoxide anion generation in mitochondria of L929 cells. Biochem J 1993; 289: 587-592.

Beyaert R, Fiers W. Molecular mechanisms of tumor necrosis factor-induced cytotoxicity: what we do understand and what we do not. FEBS Lett 1994; 340: 9-16.

Um HD, Orenstein JM, Wahl SM. Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J Immunol 1996; 156: 3469-3477.

Goossens V, Grooten J, De Vos K, Fiers W. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA. 1995; 92: 8115-8119.

Shoji Y, Uedono Y, Ishikura H, Takeyama N, Tanaka T. DNA damage induced by tumour necrosis factor-α in L929 cells is mediated by mitochondrial oxygen radical formation. Immunology 1995; 84: 543-548.

Zamzami N, Marchetti P, Castedo M, et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995; 182: 367-377.

Kohno T, Yamada Y, Hata T, et al. Relation of oxidative stress and glutatione synthesis to CD95 (Fas/APO-1)-mediated apoptosis of adult T cell leukemia cells. J Immunol 1996; 156: 4722-4728.

Muschel RJ, Bernhard EJ, Garza L, McKenna WG, Koch CJ. Induction of apoptosis at different oxygen tensions: evidence that oxygen radicals do not mediate apoptotic signaling. Cancer Res 1995; 55: 995-998.

Hug H, Enari M, Nagata S. No requirement of reactive oxygen intermediates in Fas-mediated apoptosis. FEBS Lett 1994; 351: 311-313.

Newmeyer DD, Farschon DM, Reed JC. Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 1994; 79: 353-364.

Susin SA, Zamzami N, Castedo M, et al. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95-and ceramide-induced apoptosis. J Exp Med 1997; 186: 25-37.

Zamzami N, Susin SA, Marchetti P, et al. Mitochondrial control of nuclear apoptosis. J Exp Med 1996; 183: 1533-1544.

Marchetti P, Castedo M, Susin SA, et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 1996; 184: 1155-1160.

Mayer M, Noble M. N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. Proc Natl Acad Sci USA. 1994; 91: 7496-7500.

Talley AK, Dewhurst S, Perry SW, et al. Tumor necrosis factor α-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA. Mol Cell Biol 1995; 15: 2359-2366.

Nobel CS, Burgess DH, Zhivotovsky B, Burkitt MJ, Orrenius S, Slater AF. Mechanism of dithiocarbamate inhibition of apoptosis: thiol oxidation by dithiocarbamate disulfides directly inhibits processing of the caspase-3 proenzyme. Chem Res Toxicol 1997; 10: 636-643.

Zhang P, Liu B, Kang SW, Seo MS, Rhee SG, Obeid LM. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem 1997; 272: 30615-30618.

Schulze-Osthoff K, Beyaert R, Vandevoorde V, Haegeman G, Fiers W. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J 1993; 12: 3095-3104.

Tsai JC, Jain M, Hsieh CM, et al. Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J Biol Chem 1996; 271: 3667-3670.

Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, Coffey RJ. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPβ. Nat Med 1997; 3: 1233-1241.

Gómez EO, Mendoza-Milla C, Ibarra-Sánchez MJ, Ventura-Gallegos JL, Zentella A. Ceramide reproduces late appearance of oxidative stress during TNF-mediated cell death in L929 cells. Biochem Biophys Res Commun 1996; 228: 505-509.

García-Ruiz C, Colell A, Marí M, Morales A, Fernández-Checa JC. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione. J Biol Chem 1997; 272: 11369-11377.

Arora AS, Jones BJ, Patel TC, Bronk SF, Gores GJ. Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat. Hepatology 1997; 25: 958-963.

Gudz TI, Tserng KY, Hoppel CL. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem 1997; 272: 24154-24158.

Quillet-Mary A, Jaffrézou JP, Mansat V, Bordier C, Naval J, Laurent G. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J Biol Chem 1997; 272: 21388-21395.

Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983; 52: 711-760.

van den Dobbelsteen DJ, Novel CSI, Schlegel J, Cotgreave IA, Orrenius S, Slater AFG. Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. J Biol Chem 1996; 271: 15420-15427.

Liu B, Hannun YA. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem 1997; 272: 16281-16287.

Westwick JK, Bielawska AE, Dbaibo G, Hannun YA, Brenner DA. Ceramide activates the stress-activated protein kinases. J Biol Chem 1995; 270: 22689-22692.

Kyriakis JM, Banerjee P, Nikolakaki E, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994; 369: 156-160.

Shirakabe K, Yamaguchi K, Shibuya H, et al. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J Biol Chem 1997; 272: 8141-8144.

Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326-1331.

Verheij M, Bose R, Lin XH, et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996; 380: 75-79.

Gulbins E, Bissonnette R, Mahboubi A, et al. FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity 1995; 2: 341-351.

Brenner B, Koppenhoefer U, Weinstock C, Linderkamp O, Lang F, Gulbins E. Fas-or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem 1997; 272: 22173-22181.

Huang C, Ma WY, Ding M, Bowden GT, Dong Z. Direct evidence for an important role of sphingomyelinase in ultraviolet-induced activation of c-Jun N-terminal kinase. J Biol Chem 1997; 272: 27753-27757.

Bradham CA, Stachlewitz RF, Gao W, et al. Reperfusion after liver transplantation in rats differentially activates the mitogen-activated protein kinases. Hepatology 1997; 25: 1128-1135.

Reyes JG, Robayna IG, Delgado PS, et al. c-Jun is a downstream target for ceramide-activated protein phosphatase in A431 cells. J Biol Chem 1996; 271: 21375-21380.

Dbaibo GS. Regulation of the stress response by ceramide. Biochem Soc Trans 1997; 25: 557-561.

Jarvis WD, Fornari FA Jr, Browning JL, Gewirtz DA, Kolesnick RN, Grant S. Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. J Biol Chem 1994; 269: 31685-31692.

Dickson RC, Nagiec EE, Skrzypek M, Tillman P, Wells GB, Lester RL. Sphingolipids are potential heat stress signals in Saccharomyces. J Biol Chem 1997; 272: 30196-30200.

Jenkins GM, Richards A, Wahl T, Mao C, Obeid L, Hannun Y. Involvement of yeast sphingolipids in the heat stress response of Saccharomyces cerevisiae. J Biol Chem 1997; 272: 32566-32572.

Rodriguez I, Matsuura K, Khatib K, Reed JC, Nagata S, Vassalli P. A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J Exp Med 1996; 183: 1031-1036.

Yamabe K, Kamiike W, Shimizu S, et al. Prevention of hypoxic liver injury by in vivo transfection of the human bcl-2 gene. Transplant Proc 1997; 29: 384-385.

Kostic V, Jackson-Lewis V, de Bilbao F, Dubois-Dauphin M, Przedborski S. Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997; 277: 559-562.

Martinou JC, Dubois-Dauphin M, Staple JK, et al. Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron 1994; 13: 1017-1030.

Hara H, Friedlander RM, Gagliardini V, et al. Inhibition of interleukin 1β-converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA. 1997; 94: 2007-2012.